CSOP Hang Seng Biotech ETF

Stock Code : 3174

All Information as of 31 August 2026

IMPORTANT:
CSOP Hang Seng Biotech ETF

- The Sub-Fund is not principal guaranteed and your investments may suffer losses. There is no assurance that the Sub-Fund will achieve its investment objective.
- The Index is a new index. The Sub-Fund may be riskier than other exchange traded funds tracking more established indices with longer operating history
- The investments of the Sub-Fund include biotech companies. Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products, and the ability for biotech companies to obtain regulatory approval (for example, product approval) may be long and costly. In addition, the prospects of biotech companies may significantly be impacted by technological changes, increased governmental regulations and intense competition from competitors.
- The investments of the Sub-Fund include pharmaceutical and medical devices & supplies companies. Pharmaceutical and medical devices & supplies companies are heavily dependent on patent protection. The expiration of patents may adversely affect the profitability of the companies. Many new products are subject to regulatory approval, the process of which can be long and costly and approved products are susceptible to obsolescence. Certain pharmaceutical and medical devices & supplies companies may allocate greater than usual financial resources to research and product development and experience above-average price movements associated with the perceived prospects of success of the research and development programs. Pharmaceutical and medical devices & supplies companies are also subject to heavy competitive forces that may make it difficult to raise prices. All these may have impact on the business and/or profitability of pharmaceutical and medical devices & supplies companies in which the Sub-Fund invests.
- The trading price of the Shares on the SEHK is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Sub-Fund's NAV.

Please note that the above listed investment risks are not exhaustive, and investors should read the Prospectus and the Product Key Facts in detail before making any investment decision. Investment involves risks, investment value may rise or fall. Past performance information presented is not indicative of future performance. Investors should not rely on this material alone to make investment decisions.

Investment Objective


The investment objective of the Sub-Fund is to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of Hang Seng Biotech Index (the "Index"). There is no assurance that the Sub-Fund will achieve its investment objective.

Cumulative Performance(%)[1]

	1 Month	6 Month	1 Year	3 Year	Since Scheme Change
Fund	11.78	2.26	-5.89	50.57	-11.58
Index[2]	11.87	2.79	-4.71	59.88	-10.70

Calendar Year Performance(%)[1]

	2022	2023	2024	2025	2026 YTD
Fund	-27.35	-30.65	-20.06	75.81	9.45
Index[2]	-25.67	-27.37	-17.46	74.99	10.21



Data from inception date to 31 August 2026
Source: CSOP

Fund Information

Legal structure	Open-ended Fund Company
Manager	CSOP Asset Management Limited
Total Fund Size	HKD 950.13 million
Net Asset Value	3.73
Shares Outstanding	254,763,100
Base Currency	HKD
Dividend Frequency [4]	Annually
Custodian	Cititrust Limited
Trustee	Cititrust Limited
Registrar	Tricor Investor Services Limited

Share Class Information

Trading Currency	ISIN Code	Ticker	Bloomberg Code	Trading Lot Size	Management Fee[3]	Last Distribution[4]	Ex-Date
HKD	HK0000756202	3174	3174 HK EQUITY	100	0.99% p.a.	N/A	N/A

CSOP Asset Management Limited; 2801-2803 Two Exchange Square, 8 Connaught Place, Central, Hong Kong SAR;
Tel: (852) 3406-5688 ; Website: www.csopasset.com; Email: investorservice@csopasset.com

CSOP Hang Seng Biotech ETF


Stock Code : 3174

All Information as of 31 August 2026

Top 10 Holdings

Company	% of NAV
WUXI BIOLOGICS CAYMAN INC	11.68
INNOVENT BIOLOGICS INC	11.06
BEIGENE LTD	10.72
WUXI APPTEC CO LTD-H	8.66
CHINA PHARMACEUTICAL GROUP	7.03
AKESO INC	6.25
SINO BIOPHARMACEUTICAL LIMITED	5.31
HANSOH PHARMACEUTICAL GROUP	5.05
GENSCRIPT BIOTECH CORP	4.55
3SBIO INC	3.09

Sector Breakdown



Source: Bloomberg

Disclaimer:
Investment involves risks. Investment value may rise or fall. Past performance information presented is not indicative of future performance. Investors should refer to the Prospectus and the Product Key Facts Statement for further details, including product features and risk factors. Investors should not base on this document alone to make investment decisions. The products of CSOP Asset Management Limited ("CSOP") mentioned in this document is authorized by the Securities and Futures Commission ("SFC") in Hong Kong. Such authorization does not imply any official recommendation by the SFC. This document is for informational purposes only. This document does not constitute any investment advice, advertisement or promotion of any investment products or any services, nor should it be construed as an offer, solicitation of offer, invitation, or recommendation to buy or sell any securities, funds, or any other financial instruments or enter into any transaction in any jurisdiction or country. CSOP shall not be liable for any loss, damage or expense incurred directly or indirectly as a result of the use of and/or reliance upon the whole or any part of the contents in this document. Investors should consult their own tax, legal and accounting advisors before engaging in any transaction. This document is not legally binding. This document is not applicable in jurisdictions where the distribution of this document is restricted. The product is only available in jurisdictions where it can be lawfully provided. For index provider disclaimers, please refer to the offering documents of the relevant funds. This document has not been reviewed by the Securities and Futures Commission in Hong Kong.
Issuer: CSOP Asset Management Limited

Footnote:

1. Product performance is calculated in HKD on NAV-to-NAV basis with dividend re-invested.
2. With effect from 15 September 2025, the Index of the Sub-Fund changed from Solactive China Healthcare Disruption Index to Hang Seng Biotech Index. As a result of the change of the Index and the objective and investment strategy of the Sub-Fund, past performance of the Sub-Fund prior to 15 September 2025 was achieved under circumstances which no longer apply. Investors should exercise caution when considering the past performance of the Sub-Fund prior to 15 September 2025.
3. Please refer to the CSOP website and Product's offering document for detailed information.
4. The frequency of dividend distribution may change at the discretion of the Manager. Please refer to the CSOP website and Distribution Announcements for distribution history.